Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association
interstitial lung disease :: Article Creator Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd ConferencesESMO Congress Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd. Before starting them on trastuzumab deruxtecan (T-DXd; Enhertu), oncology nurses should discuss the use of anti-emetics as well as the potential for hair loss and interstitial lung disease with their patients, explained Nancy U. Lin, MD. Lin is a professor of Medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston. At the 2024 ESMO Congress, she discussed findings from the phase 3b/4 DESTINYBreast-12 trial, which showed that trastuzumab deruxtecan led to promising response rates and progression-free survival in patients with HER2-positive metastatic breast cancer—even in the presence of brain metast...